Matthew Holderfield

3.7k citations

25 papers · 2.2k indexed · 1 hit paper · h-index 17

Co-authors: Frank McCormick Christopher C.W. Hughes Martin McMahon Marian M. Deuker Erin M. Conn Martin N. Nakatsu Richard C.A. Sainson Darrin D. Stuart
Topics: Melanoma and MAPK Pathways (9 papers)Protein Kinase Regulation and GTPase Signaling (8 papers)Angiogenesis and VEGF in Cancer (5 papers)
Cited by: Molecular Biology Oncology Cancer Research
Journals: Cell Proceedings of the National Academy of Sciences Nature reviews. Cancer
Partner nations: United States Switzerland Finland

In The Last Decade

Matthew Holderfield

25 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond

2014 618 citations Matthew Holderfield, Marian M. Deuker et al. Nature reviews. Cancer profile →

Peers

Countries citing papers authored by Matthew Holderfield

Since Specialization

Citations

This map shows the geographic impact of Matthew Holderfield's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Holderfield with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Holderfield more than expected).

Fields of papers citing papers by Matthew Holderfield

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Holderfield. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Holderfield. The network helps show where Matthew Holderfield may publish in the future.

Co-authorship network of co-authors of Matthew Holderfield

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Holderfield. A scholar is included among the top collaborators of Matthew Holderfield based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Holderfield. Matthew Holderfield is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	92 (PB080): Selective Inhibition of Active KRASG13C with RMC-8839 Reveals an Increased Dependence of Codon-13 KRAS-Mutant Cancers on Wild- Type RAS Isoforms 2024 ·European Journal of Cancer ·Kenneth B. Seamon,Sohini Chakraborty,(unknown),Jim Cregg,A. Tomlinson,Nicole Nasholm,Mallika Singh,Jacqueline A.M. Smith,Matthew Holderfield,David Wildes	1
2	Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 Inhibition 2021 ·SLAS DISCOVERY ·Lo Lai,(unknown),Kanika Sharma,(unknown),(unknown),(unknown),N. Muzet,(unknown),Renaud Morales,E.K. Rooney,Nicolas Basse,Ming Yi,Frédéric Lacroix,Matthew Holderfield,Walter Englaro,Christophe Marcireau,Laurent Debüssche,Dwight V. Nissley,Frank McCormick	1
3	Homogeneous Dual-Parametric-Coupled Assay for Simultaneous Nucleotide Exchange and KRAS/RAF-RBD Interaction Monitoring 2020 ·Analytical Chemistry ·Kari Kopra,(unknown),(unknown),(unknown),(unknown),William Gillette,Arto T. Pulliainen,Matthew Holderfield,Harri Härmä	37
4	Abstract B18: Clostridium perfringens lethal toxin specifically targets RAS and disrupts RAS signaling pathway 2020 ·Molecular Cancer Research ·(unknown),Ming Yi,(unknown),Matthew Holderfield	1
5	KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis 2019 ·Proceedings of the National Academy of Sciences ·(unknown),Timothy H. Tran,Srisathiyanarayanan Dharmaiah,Robert M. Stephens,Frank McCormick,Dhirendra K. Simanshu,Matthew Holderfield	94
6	Label-Free Time-Gated Luminescent Detection Method for the Nucleotides with Varying Phosphate Content 2018 ·Sensors ·Kari Kopra,(unknown),(unknown),(unknown),Sakari Kulmala,Matthew Holderfield,Harri Härmä	2
7	New weapons to penetrate the armor: Novel reagents and assays developed at the NCI RAS Initiative to enable discovery of RAS therapeutics 2018 ·Seminars in Cancer Biology ·Dominic Esposito,Andrew G. Stephen,Thomas J. Turbyville,Matthew Holderfield	11
8	Efforts to Develop KRAS Inhibitors 2017 ·Cold Spring Harbor Perspectives in Medicine ·Matthew Holderfield	32
9	Inhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-Induced Phospho-Regulatory Circuit 2016 ·Molecular Cell ·Daniel A. Ritt,Maria Teresa Abreu‐Blanco,Lakshman Bindu,David Durrant,Ming Zhou,Suzanne I. Specht,Andrew G. Stephen,Matthew Holderfield,Deborah K. Morrison	76
10	Farnesylated and methylated KRAS4b: high yield production of protein suitable for biophysical studies of prenylated protein-lipid interactions 2015 ·Scientific Reports ·William Gillette,Dominic Esposito,(unknown),Patrick Alexander,Lakshman Bindu,(unknown),Oleg Chertov,Peter Frank,(unknown),(unknown),Zhaojing Meng,(unknown),Que N. Van,Rodolfo Ghirlando,Matthew J. Fivash,Dwight V. Nissley,Frank McCormick,Matthew Holderfield,Andrew G. Stephen	56
11	K-Ras Promotes Tumorigenicity through Suppression of Non-canonical Wnt Signaling 2015 ·Cell ·(unknown),Matthew Holderfield,Jacqueline Galeas,Reyno Delrosario,Minh D. To,Allan Balmain,Frank McCormick	155
12	Vemurafenib Cooperates with HPV to Promote Initiation of Cutaneous Tumors 2014 ·Cancer Research ·Matthew Holderfield,Edward Lorenzana,Ben Weisburd,(unknown),Lise Boussemart,Ludovic Lacroix,Gorana Tomasic,Michel Fãvre,Stéphan Vagner,Caroline Robert,Majid Ghoddusi,(unknown),Nancy Pryer,Frank McCormick,Darrin D. Stuart	20
13	Transcriptome-wide characterization of the eIF4A signature highlights plasticity in translation regulation 2014 ·Genome biology ·(unknown),(unknown),Matthew Holderfield,Carolina Arias,Eric Fang,Joseph L. DeRisi,Abdallah Fanidi	145
14	Mechanism and consequences of RAF kinase activation by small-molecule inhibitors 2014 ·British Journal of Cancer ·Matthew Holderfield,Tobi Nagel,Darrin D. Stuart	90
15	Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyondbreakdown → 2014 ·Nature reviews. Cancer ·Matthew Holderfield,Marian M. Deuker,Frank McCormick,Martin McMahon	618
16	Interferon-Induced Transmembrane Protein 1 Regulates Endothelial Lumen Formation During Angiogenesis 2014 ·Arteriosclerosis Thrombosis and Vascular Biology ·(unknown),Mary E. Ziegler,Xiaofang Chen,Matthew Holderfield,(unknown),Ashley Fong,Katrina M. Welch-Reardon,Jackie Papkoff,Christopher C.W. Hughes	30
17	RAF Inhibitors Activate the MAPK Pathway by Relieving Inhibitory Autophosphorylation 2013 ·Cancer Cell ·Matthew Holderfield,Hanne Merritt,John S.D. Chan,Marco Wallroth,Laura Tandeske,Huili Zhai,John E. Tellew,Stephen Hardy,Mohammad Hekmat-Nejad,Darrin D. Stuart,Frank McCormick,Tobi Nagel	96
18	TNF primes endothelial cells for angiogenic sprouting by inducing a tip cell phenotype 2008 ·Blood ·Richard C.A. Sainson,Douglas A. Johnston,(unknown),Matthew Holderfield,Martin N. Nakatsu,(unknown),Jaeger Davis,Erin M. Conn,Christopher C.W. Hughes	274
19	HESR1/CHF2 suppresses VEGFR2 transcription independent of binding to E-boxes 2006 ·Biochemical and Biophysical Research Communications ·Matthew Holderfield,(unknown),Hiroki Kokubo,Michael T. Chin,Randy L. Johnson,Christopher C.W. Hughes	33
20	Cell‐autonomous notch signaling regulates endothelial cell branching and proliferation during vascular tubulogenesis 2005 ·The FASEB Journal ·Richard C.A. Sainson,Jason Aoto,Martin N. Nakatsu,Matthew Holderfield,Erin M. Conn,Erich Koller,Christopher C.W. Hughes	191

About Matthew Holderfield

Matthew Holderfield is a scholar working on Molecular Biology, Pathology and Forensic Medicine and Oncology, having authored 25 papers that have together received 2.2k indexed citations. Recurring topics across this work include Melanoma and MAPK Pathways (9 papers), Protein Kinase Regulation and GTPase Signaling (8 papers) and Angiogenesis and VEGF in Cancer (5 papers). The work is most often cited by research in Molecular Biology (1.7k citations), Oncology (564 citations) and Cancer Research (266 citations). Matthew Holderfield has collaborated with scholars based in United States, Switzerland and Finland. Frequent co-authors include Frank McCormick, Christopher C.W. Hughes, Martin McMahon, Marian M. Deuker, Erin M. Conn, Martin N. Nakatsu, Richard C.A. Sainson, Darrin D. Stuart, Tobi Nagel and Douglas A. Johnston. Their work appears in journals such as Cell, Proceedings of the National Academy of Sciences and Nature reviews. Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact